High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site

Journal of Radiation Research
Dinara ZharlyganovaMasaharu Hoshi

Abstract

It is known that bone marrow is a sensitive organ to ionizing radiation, and many patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) have been diagnosed in radiation-treated cases and atomic bomb survivors in Hiroshima and Nagasaki. The AML1/RUNX1 gene has been known to be frequently mutated in MDS/AML patients among atomic bomb survivors and radiation therapy-related MDS/AML patients. In this study, we investigated the AML1 mutations in radiation-exposed patients with MDS/AML among the residents near the Semipalatinsk Nuclear Test Site (SNTS), where the risk of solid cancers and leukemias was increased due to the radiation effects. AML1 mutations were identified in 7 (39%) of 18 radiation-exposed MDS/AML patients. In contrast, no AML1 mutation was found in 13 unexposed MDS/AML cases. The frequency of AML1 mutations in radiation-exposed patients with MDS/AML was significantly higher compared with unexposed patients (p < 0.05).We also found a significant correlation between individual estimated doses and AML1 mutations (p < 0.05). Considering these results, AML1 point mutations might be a useful biomarker that differentiates radio-induced MDS/AML from spontaneous MDS/AML.

References

Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
May 17, 2002·Radiation and Environmental Biophysics·B Grosche
May 17, 2002·Radiation and Environmental Biophysics·K GordeevL Anspaugh
Mar 31, 2006·Journal of Radiation Research·Steven L SimonSergey Shinkarev
Mar 31, 2006·Journal of Radiation Research·Kassym ZhumadilovMasaharu Hoshi
Mar 31, 2006·Journal of Radiation Research·Natalia Semioshkina, Gabrielle Voigt
Jan 26, 2007·Nature Reviews. Cancer·Seth J CoreyAaron D Schimmer

❮ Previous
Next ❯

Citations

Jan 27, 2011·Journal of Cellular Biochemistry·Yuka Harada, Hironori Harada
Sep 22, 2017·International Journal of Molecular Sciences·Maliha KhanCourtney D DiNardo
Jan 13, 2018·Frontiers in Cell and Developmental Biology·Dana C Bellissimo, Nancy A Speck
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masako IwanagaMasao Tomonaga
Dec 7, 2011·PloS One·Xiongwei CaiNancy A Speck
Jul 26, 2015·Annals of Hematology·Daniil F GluzmanNataliia I Ukrainskaya
Apr 1, 2009·Journal of Cellular Physiology·Yuka Harada, Hironori Harada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.